Il 18 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Compugen Ltd. has entered another collaboration, this time exclusively licensing a preclinical antibody program against an IL-18 binding protein with Gilead Sciences Inc. Compugen will handle ongoing preclinical development and a phase I study of COM-503 to treat tumors, then Gilead receives to sole right to further continue developing the asset. Compugen is getting an up-front $60 million and is eligible for a $30 million milestone payment should the IND clear in 2024. Compugen also is eligible for $758 million in development, regulatory and commercial milestones, putting the deal value at $8...

Congressman Brian Mast says his Northern Estuaries Restoration Plan (NERP) will force the U.S. Army Corps of Engineers to take action to address harmful algal blooms and end the toxic discharges that continue to plague the northern estuaries.

Congressman Brian Mast says his Northern Estuaries Restoration Plan (NERP) will force the U.S. Army Corps of Engineers to take action to address harmful algal blooms and end the toxic discharges that continue to plague the northern estuaries.

Congressman Brian Mast says his Northern Estuaries Restoration Plan (NERP) will force the U.S. Army Corps of Engineers to take action to address harmful algal blooms and end the toxic discharges that continue to plague the northern estuaries.

Congressman Brian Mast says his Northern Estuaries Restoration Plan (NERP) will force the U.S. Army Corps of Engineers to take action to address harmful algal blooms and end the toxic discharges that continue to plague the northern estuaries.